SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing significant selling pressure and negative sentiment, driven largely by reports that hyperscalers like Meta are exploring the commercialization of their own excess AI compute capacity. Shareholders are actively debating the company's long-term viability, expressing mounting frustration over persistent price declines and concerns regarding management's capital allocation and lack of major deal announcements.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is seeing intense trading activity as investors position themselves ahead of upcoming quarterly delivery reports, with community members fiercely debating whether the stock's recent surge reflects genuine growth or a temporary rally fueled by options-driven speculation. The conversation is dominated by contrasting sentiment, where bulls are betting on a major breakout supported by potential delivery beats, while skeptics warn of significant downside risk and label the current valuation as disconnected from fundamentals.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently the center of intense debate as traders weigh the potential market impacts of the EU's MiCA deadline against ongoing volatility in crypto and broader tech sector rotations. While some community members point to the stock's role as critical infrastructure for institutional stablecoin projects as a long-term catalyst, others remain sharply focused on short-term technical resistance and persistent downward price action.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently surging as investors bet on potential upcoming catalysts, including global expansion efforts and positive clinical trial momentum involving the company's immunotherapy platform. The community is actively discussing a possible short squeeze, fueled by heavy options activity and high short interest, while celebrating recent media exposure highlighting the potential of NK cell therapies.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group shares are experiencing significant volatility following reports that Meta plans to commercialize its excess AI compute capacity, which investors fear could increase market competition and pressure neocloud profit margins. Despite the selling pressure, the community is heavily divided, with many long-term holders dismissing the news as market manipulation and an overblown 'ghost story,' arguing that existing multi-year capacity contracts and structurally tight AI demand remain fundamentally intact.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is facing heightened investor attention as the stock navigates a complex environment of resilient premium travel demand against significant headwinds from volatile jet fuel costs and geopolitical tensions. Market participants are actively debating the company's ability to maintain margin strength through pricing power and capacity adjustments while monitoring institutional positioning and institutional momentum during this period of high industry uncertainty.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors weigh significant collaborative momentum, including a new integration with Lockheed Martin and ongoing demand for its ISR and counter-UAS platforms, against persistent retail concerns regarding share dilution and insider selling. Community discourse is highly polarized, with intense debates focusing on whether the company's expanding backlog and high-profile defense partnerships justify current valuations or if aggressive short interest and structural headwinds will continue to pressure the price.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market interest driven by recent FDA approvals for its diagnostic platforms and ongoing strategic partnerships with pharmaceutical leaders. The community is heavily focused on the company's high short interest and its potential as a long-term play in AI-integrated healthcare, with traders closely monitoring upcoming events and technical breakouts for momentum signals.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is currently trending due to a wave of positive analyst coverage, including a new Buy rating and price target from Wedbush, coupled with intense speculation regarding its unique position as the only pure-play neutral-atom quantum company involved in recent high-level government executive orders. The community is actively debating the stock's long-term potential in the defense and space sectors while navigating frustration over volatility and the impact of significant short interest on recent price action.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant volatility driven by broader semiconductor sector rotation and investor concerns regarding AI oversupply, particularly following reports of competitors seeking to monetize excess compute capacity. While many investors are panicking over the sharp correction, others view the pullback as a necessary consolidation and a prime accumulation opportunity, citing Micron's robust long-term contracts and fundamental positioning in the high-demand memory market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%

Equity

The company reported that the U.S. Food and Drug Administration aligned with the company on several key aspects of the Phase 3 study, which is expected to begin in mid-2027.

Cognition Therapeutics (CGTX) to Release Earnings on Wednesday

Cognition Therapeutics (NASDAQ:CGTX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-cognition-therapeutics-inc-stock...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Moderate Buy" by Analysts

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the four analysts that are covering the firm, MarketBeat reports. One research...

Insider Buying: Cognition Therapeutics (NASDAQ:CGTX) CEO Acquires 9,175 Shares of Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares of the company's stock in a transaction dated Thursday, April 16th. The shares were acquired at an...

John Brendan Doyle Purchases 10,000 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CFO John Brendan Doyle bought 10,000 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average cost of $1.13 per share, with a total value of $11,300.00. Following the completion of...

Lisa Ricciardi Acquires 9,175 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi acquired 9,175 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The shares were purchased at an average price of $1.10 per share, with a total value of $10,092.50. Following the...

Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans

Cognition Therapeutics (NASDAQ:CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage...

Q1 Earnings Forecast for CGTX Issued By HC Wainwright

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Cognition Therapeutics in a research report issued on Friday...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four research firms that are covering the stock, MarketBeat reports. One...

Cognition Therapeutics (NASDAQ:CGTX) Receives Buy Rating from Chardan Capital

Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of Cognition Therapeutics in a research report on Friday...

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

Cognition Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CGTXCognition Therapeutics Inc

Fundamentals

Latest CGTX News